Quote:
Originally Posted by TheseGoTo11
So the larger question is can the second tier - NY, Seattle, DC, Philly, LA, Raleigh/Durham - which tend to be stronger at basic research, expand deeper into commercialized biopharma. It didn't happen in software, where the Bay Area's advantages got reinforced, and its share of VC actually grew as the industry expanded.
|
Philadephia completely blew its early lead in computing technology, and it seems to me that the region's academic and business leaders are determined not to do the same thing with gene therapy; I note that that
GEN report notes that Philly-based Spark Therapeutics received the first FDA approval for a genetic treatment for a disease in 2018.
That's still a specialized area of biopharma, however.
I do find it interesting to note that Greater Philadelphia not only ranks sixth on that list but also sixth in every category that went into the rankings save patents, where it ranks seventh.
It is also IMO interesting to note that the Top 10 on that list were the Top 10 on the previous list, with only the rank order of the cities altered. This seems to me to suggest that any other region seeking to break into the top ranks for biomedicine will have a hard time doing so.